London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
siso29 talks rubbish this company is well run ,and a important assistant to the nhs and constantly assisting in saving lives ,the company for last 2 years have made great strides forward and are profit making .should be well supported and can go upwards medium term
I would sell asap - before it goes to 4p again - its going down the tubes. Dont kid yourself its all being manipulated nicely. They have missed the boat on R & D so it will inevitably decline
Source BioScience achieves double digit Q1 revenue growth AND ' existing institutional shareholders have increased their holdings and, in addition, several new institutions have become shareholders' Looking good, wait for the market.
Mr S.Varkey down from 17m to 3m. don't know much about him but he's been a major shareholder for at least 4 years. Guess he's trousered a fair profit. Anyway, a lot of ii big dealings of late. Any holders of SBS care?
changed hands today in 10 minutes. On 2nd May : Texas Instruments sold out Killik and L & G increased holdings Henderson went to over 10% in voting rights - checking out if this also means shares increased.
shares changed hands today - bit over the average! Expect an explanatory RNS this week or Monday.
You're probably right about transfers, when I match up the trades they all seem to cancel out, e.g 2 x 1,600,000 , 2 x 682,222 and add up 3 trades they total 8,743,166 - which is the biggest trade. Suppose we can expect a holdings RNS in a day or two?
though, about 20% of free float - 23 m of 119m - but total shares = 203m Last RNS was about Killik's holding, around 3% No change to sp anyway
Paul Hill - MoneyWeek Gamble of the Week (should be Harry Hill - Lol) Good articlestating a lot of medical facts and figures supporting SBS's case. Finishes with : "Yet with it's main markets growing at 10% per year, it looks well placed to benefit from it's expertise in cancer and molecular diagnostics. Nplus1 Brewin has a price target of 12p. SPECULATIVE BUY at 7.25p" You can't get them for that price now!
N + 1 Brewin initiates buy on Source Bioscience, target price 12p
Sorry, that table did not copy well. Below are the important bits ! Adjusted operating profit* 2011 - 461,000 2010 - 170,000 = +171%! Adjusted profit after tax* 2011 - £610,000 2010 - 267,000 = +128% ! Impressive stuff.
2011 2010 % change £'000 £'000 Revenue 15,192 13,487 +13% Gross profit 6,751 5,821 +16% (Loss)/profit after tax (2,795) 93 - Adjusted operating profit* 461 170 +171% Adjusted profit after tax* 610 267 +128% Adjusted EBITDA* 1,860 1,256 +48%
Post-period event * Access to FocalPoint is the determining factor in winning the University Hospital of North Staffordshire NHS Trust's liquid based cytology contract; this is the first Trust to switch liquid based cytology technology and is worth £0.3 million per annum Laurie Turnbull, Chairman of Source BioScience, said: "2011 was another year of improvements to the business and strategic progression for Source BioScience. Revenue and operating profit, before the impact of non-recurring items, have increased again and the Group is in a strong financial position. "Key achievements have been the launch of the Overnight Service and GenomeCube which give us a dominant position as a world class provider of sequencing services and genomic products. In addition, our Healthcare division has the potential for significant growth with the approval of BD FocalPoint™ in the cervical cancer screening programme. "Significant opportunities are apparent across all areas of the Group in line with the increasing demands of the healthcare and life sciences markets for faster, more efficient and more accurate molecular diagnostics and gene sequencing services."
The Board of Source BioScience plc (LSE: SBS), the international diagnostic and genetic analysis business announces its unaudited preliminary results for the year ended 31 December 2011. Financial highlights * Revenue increased by 13% to £15.2 million (2010: £13.5 million) * Adjusted operating profit* of £0.5 million (2010: £0.2 million) * Adjusted EBITDA* increased by 48% to £1.9 million (2010: £1.3 million) * Adjusted profit after tax* of £0.6 million (2010: £0.3 million) * Loss after tax of £2.8 million (2010: profit £0.1 million) * Cash generated from operating activities of £0.6 million (2010: £0.9 million) * Cash balance at 31 December 2011 of £1.1 million (2010: £4.2 million) * Purchase of the freehold land and buildings of the Head Office premises in Nottingham, eliminating the 17 year lease obligation and increasing EBITDA by £0.5 million per annum from 2012 * Integration and associated restructuring of the imaGenes business was completed as planned; expected to deliver annualised cost savings in the region of £0.7 million *Results are stated after eliminating non-recurring restructuring costs of £0.6 million associated with the planned integration of the acquired imaGenes business and the impact of a charge of £2.8 million to reflect the fair value of the Head Office premises purchased during the year, as previously announced. Operational highlights * Major developments in LifeSciences business driving growth: * Overnight Service for DNA sequencing launched in the UK and Germany, providing the fastest available turnaround times to the life sciences research community * The world's largest integrated clone and antibody library is now available via GenomeCube, our proprietary search engine and bioinformatics tool; positive feedback from customers and demand growing * In the Healthcare business, contracts worth over £0.5 million per annum already signed with NHS Trusts following approval of the FocalPoint automated imaging platform for cervical cancer screening; further interest from other NHS Trusts expected
Yeah, spotted that big buy on Thursday for £253,750 - wasn't me! Somebody is CONFIDENT.
So that's 3.66 mln shares bought today to no sells. Whiff of a contract per chance? Come on everyone! back to this board.
I know chap, it was toungue in cheek. I was as surprised as others to see this dip but it seems to have come back this morning. A nice fat NHS contract first thing Monday morning would start the week very nicely, eh! Good luck to you. Regards, AdJ
The comment about availability refers to specific time. I posted that comment after having difficulties buying myself gl
"Difficult to pick up these shares in any reasonable amount" what's the dilly someone? Seems someone can buy 3 million!
Do you think it could of been a negotiation between two market makers?
Why do you think them big buys has not effected the sp at all?
Tom Bulford should be looking at as part of his search for top notch Biotech companies imho. A great change from the usual debt ridden, negligible revenue candidates that are usual for the sector. SBS is going places imho
We should be getting multiple newsflow in the coming weeks & months regarding further contracts for BDFocalPoint and consistent with the ongoing discussions currently taking place. Difficult to pick up these shares in any reasonable amount so comfortable securing my holding now and waiting. A very solid & industry leading healthcare / biotech company